Farther Finance Advisors’s Usana Health Sciences USNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$11.5K Sell
792
-1,172
-60% -$20.2K ﹤0.01% 4534
2026
Q2
$41.9K Buy
1,964
+1,647
+520% +$31K ﹤0.01% 3386
2026
Q1
$5.46K Sell
317
-528
-62% -$10.5K ﹤0.01% 4445
2025
Q4
$16.6K Buy
845
+306
+57% +$6.35K ﹤0.01% 3561
2025
Q3
$14.8K Sell
539
-198
-27% -$6.09K ﹤0.01% 3223
2025
Q2
$22.5K Buy
737
+263
+55% +$7.47K ﹤0.01% 2604
2025
Q1
$12.9K Buy
474
+76
+19% +$2.41K ﹤0.01% 2609
2024
Q4
$14.3K Hold
398
– – ﹤0.01% 2222
2024
Q3
$15.1K Buy
398
+388
+3,880% +$15.9K ﹤0.01% 2198
2024
Q2
$448 Sell
10
-9
-47% -$414 ﹤0.01% 3307
2024
Q1
$911 Buy
19
+9
+90% +$441 ﹤0.01% 2811
2023
Q4
$536 Sell
10
-12
-55% -$607 ﹤0.01% 2954
2023
Q3
$1.29K Hold
22
– – ﹤0.01% 2003
2023
Q2
$1.39K Hold
22
– – ﹤0.01% 1876
2023
Q1
$1.38K Hold
22
– – ﹤0.01% 1760
2022
Q4
$1.17K Buy
+22
New +$1.19K ﹤0.01% 1610

Other funds holding USNA

Farther Finance Advisors's USNA Position: Q3 2026 in Review

Farther Finance Advisors reduced its Usana Health Sciences (USNA) stake by 60% in Q3 2026, selling an estimated $20.2K and leaving 792 shares worth $11.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4534.

Farther Finance Advisors first reported a position in USNA in Q4 2022 and has held it in 16 quarters since. The position peaked at $41.9K in Q2 2026. 6 funds tracked by Wall St. Rank hold USNA as of Q3 2026.

  • Farther Finance Advisors held 792 shares of Usana Health Sciences worth $11.5K as of Q3 2026.
  • Farther Finance Advisors sold 1,172 Usana Health Sciences shares in Q3 2026, an estimated $20.2K.
  • Usana Health Sciences made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #4534 holding.
  • Farther Finance Advisors first reported a position in Usana Health Sciences in Q4 2022 and has held it in 16 quarters since.
  • Farther Finance Advisors's Usana Health Sciences position peaked at $41.9K in Q2 2026.
  • 6 funds tracked by Wall St. Rank held Usana Health Sciences as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.